Guan Xiaowei, Vengoechea Jaime, Zheng Siyuan, Sloan Andrew E, Chen Yanwen, Brat Daniel J, O'Neill Brian Patrick, de Groot John, Yust-Katz Shlomit, Yung Wai-Kwan Alfred, Cohen Mark L, Aldape Kenneth D, Rosenfeld Steven, Verhaak Roeland G W, Barnholtz-Sloan Jill S
Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio, United States of America.
Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio, United States of America; Department of Internal Medicine, University Hospitals Case Medical Center, Cleveland, Ohio, United States of America.
PLoS One. 2014 Mar 10;9(3):e91216. doi: 10.1371/journal.pone.0091216. eCollection 2014.
Gliomas are the most common primary malignant brain tumors in adults with great heterogeneity in histopathology and clinical course. The intent was to evaluate the relevance of known glioblastoma (GBM) expression and methylation based subtypes to grade II and III gliomas (ie. lower grade gliomas).
Gene expression array, single nucleotide polymorphism (SNP) array and clinical data were obtained for 228 GBMs and 176 grade II/II gliomas (GII/III) from the publically available Rembrandt dataset. Two additional datasets with IDH1 mutation status were utilized as validation datasets (one publicly available dataset and one newly generated dataset from MD Anderson). Unsupervised clustering was performed and compared to gene expression subtypes assigned using the Verhaak et al 840-gene classifier. The glioma-CpG Island Methylator Phenotype (G-CIMP) was assigned using prediction models by Fine et al.
Unsupervised clustering by gene expression aligned with the Verhaak 840-gene subtype group assignments. GII/IIIs were preferentially assigned to the proneural subtype with IDH1 mutation and G-CIMP. GBMs were evenly distributed among the four subtypes. Proneural, IDH1 mutant, G-CIMP GII/III s had significantly better survival than other molecular subtypes. Only 6% of GBMs were proneural and had either IDH1 mutation or G-CIMP but these tumors had significantly better survival than other GBMs. Copy number changes in chromosomes 1p and 19q were associated with GII/IIIs, while these changes in CDKN2A, PTEN and EGFR were more commonly associated with GBMs.
GBM gene-expression and methylation based subtypes are relevant for GII/III s and associate with overall survival differences. A better understanding of the association between these subtypes and GII/IIIs could further knowledge regarding prognosis and mechanisms of glioma progression.
胶质瘤是成人中最常见的原发性恶性脑肿瘤,在组织病理学和临床病程方面具有很大的异质性。目的是评估已知的胶质母细胞瘤(GBM)基于表达和甲基化的亚型与II级和III级胶质瘤(即低级别胶质瘤)的相关性。
从公开可用的伦勃朗数据集中获取了228例GBM和176例II/III级胶质瘤(GII/III)的基因表达阵列、单核苷酸多态性(SNP)阵列及临床数据。另外两个具有异柠檬酸脱氢酶1(IDH1)突变状态的数据集被用作验证数据集(一个公开可用数据集和一个来自MD安德森癌症中心的新生成数据集)。进行了无监督聚类,并与使用Verhaak等人的840基因分类器指定的基因表达亚型进行比较。使用Fine等人的预测模型来确定胶质瘤CpG岛甲基化表型(G-CIMP)。
基因表达的无监督聚类与Verhaak 840基因亚型分组一致。GII/III级胶质瘤优先被归为具有IDH1突变和G-CIMP的神经干细胞样亚型。GBM在四种亚型中分布均匀。神经干细胞样、IDH1突变、G-CIMP的GII/III级胶质瘤的生存率显著高于其他分子亚型。只有6%的GBM是神经干细胞样的,并且具有IDH1突变或G-CIMP,但这些肿瘤的生存率显著高于其他GBM。染色体1p和19q的拷贝数变化与GII/III级胶质瘤相关,而细胞周期蛋白依赖性激酶抑制剂2A(CDKN2A)、磷酸酶和张力蛋白同源物(PTEN)及表皮生长因子受体(EGFR)的这些变化更常与GBM相关。
基于GBM基因表达和甲基化的亚型与GII/III级胶质瘤相关,并与总体生存差异相关。更好地理解这些亚型与GII/III级胶质瘤之间的关联,可能会进一步增进对胶质瘤预后和进展机制的认识。